Share on:
So far in 2024, there have been 37 new drug approvals by the FDA. This means that novel treatment options are available for patients that may substantially improve the public health. From drugs that treat pulmonary arterial hypertension to drugs that treat Alzheimer’s disease, the new drugs introduced to the market will likely have a profound impact on a wide range of diseases.
To be relevant practitioners, pharmacists and pharmacy technicians need to have a thorough understanding of the newly approved medications. The purpose of this knowledge-based activity is to educate pharmacists and pharmacy technicians on some of the recently approved drugs of 2024. More specifically, there will be information provided on the mechanism of action, effectiveness, safety, and handling of newly approved drugs.
This knowledge-based continuing pharmacy education (CPE) activity focusing on new drugs introduced in 2024 is approved for 3 live contact hours (0.3 CEUs). It is intended and appropriate for all pharmacists and pharmacy technicians. To receive credit, participants must attend the entire session and complete activity assessments.
